HAGAR
Israel - Tel AvivBiotechnology
Focus: HAGAR is an Israeli biotech company focused on glucose monitoring devices and metabolic disease therapeutics, currently in early-to-mid stage clinical development with a diverse pipeline.
Profile data last refreshed 3h ago · AI intelligence enriched 2w ago
Funding Stage
PUBLIC
Total Funding
$5M
Open Jobs
0
About HAGAR
AI assessmentNot HiringNo open roles listed right now. Follow HAGAR to get notified when they start hiring — the background below is worth knowing for when they do.
Why Work Here
Data completeness
1/9 — Limited
Company HealthSolid
Pipeline
Mid-stage
1 Phase 3+
LOE Risk
Protected
No near-term cliffs
Hiring
0 open
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Pipeline & Clinical Trials
Clinical Findings and Albuminuria as Predictors of Acute Kidney Injury in Patients With Acute Heart
Heart FailureClinical Trials (1)
NCT06621862Clinical Findings and Albuminuria as Predictors of Acute Kidney Injury in Patients With Acute Heart Failure
N/AHelp build intelligence for HAGAR
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.